Angelini Pharma and JCR Pharmaceuticals Forge Global Alliance to Create Innovative Treatments for Epilepsy

Angelini Pharma and JCR Pharmaceuticals Co., Ltd. (TSE 4552) have joined forces to develop and commercialize cutting-edge biologic therapies that use J-Brain Cargo®, a revolutionary technology that can penetrate the blood-brain barrier, for the treatment of epilepsy. This exclusive global partnership marks a milestone in the medical field, as the development of these treatments will provide hope to those affected by this neurological disorder.

JCR and Angelini Pharma have joined forces to discover and develop innovative brain-penetrant biologic therapeutics utilizing JCR’s cutting-edge J-Brain Cargo® technology. This revolutionary technology enables the transportation of biotherapeutics directly into the central nervous system.

Should pre-clinical trials prove successful, Angelini Pharma will have the option to license the therapeutic candidates and further advance them into clinical development and global commercialization outside of Japan.

JCR and its partner are thrilled to announce their collaboration agreement, which includes reimbursement of research expenses, an upfront payment, and the potential for up to US$505.5 million in additional payments upon achieving development and commercial goals.

In addition, JCR will be eligible to receive tiered royalties on post-approval net sales. This agreement is sure to be a major boost to JCR’s business.

Epilepsy is one of the most common chronic neurological diseases, and its impact on society has been increasingly recognized in the past decade. Its high mortality rate and disability burden demand more research to develop targeted solutions for this underserved patient community.

To accelerate the search for critically needed treatments, Angelini Pharma has joined forces with JCR, a biotechnological leader, to explore the use of biologics in this field. Together, both parties will combine their expertise to bring hope to those living with epilepsy.

The blood-brain barrier has long eluded clinical researchers searching for treatments for neurological diseases. Now, thanks to our exciting new partnership with Angelini Pharma, we can unlock new pathways to develop therapies that can help these patients.

Our proprietary J-Brain Cargo® technology holds the promise of revolutionizing the treatment of central nervous system disorders, and when combined with Angelini Pharma’s expertise in neurological diseases, we can create new treatment possibilities for those with epilepsy.

Epilepsy is a devastating neurological condition that affects over 50 million people around the world. Seizures can cause significant disruption to a person’s life, and current treatments are not always successful in controlling them. This means that there is an urgent need for new therapies that can offer more effective relief from the debilitating impact of this condition.

About Angelini Pharma

Angelini Pharma is a leading international pharmaceutical company, part of the multi-business Angelini Industries. With a focus on Brain Health, Mental Health and Epilepsy, as well as Consumer Health, the company has been researching and developing innovative health solutions since the beginning of the 20th century.

Today, Angelini Pharma operates in 20 countries, with its products marketed in over 70 countries through strategic alliances with major pharmaceutical groups – employing more than 3,000 people worldwide.

About Angelini Industries

Since its foundation in Ancona in 1919 by Francesco Angelini, Angelini Industries has grown into a global powerhouse, employing 5,800 people across 21 countries and generating revenues of over 2 billion euros.

Its commitment to investment, research and development, and deep market knowledge has established them as a leader in the health, industrial technology, and consumer goods sectors. With a targeted growth strategy, Angelini Industries is a shining example of Italian excellence in its respective industries.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global leader in specialty pharmaceuticals, challenging the status quo and pushing the boundaries to improve the lives of those affected by rare and genetic diseases. With 48 years of experience in Japan, the company is now expanding its reach to the US, Europe, and Latin America to provide next-generation therapies to the world.

JCR is committed to its core values of reliability, confidence, and persistence, which allows them to provide their stakeholders, including employees, partners, and patients, with the best possible outcomes. With a focus on accelerating medical advancement, JCR is dedicated to expanding the possibilities for patients and creating a brighter future.

Leave a Comment